Advertisements

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Category: press-releasesSource: businesswireindiaMar 20th, 2017

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2017

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Category: press-releasesSource: businesswireindiaAug 24th, 2017

'More than Systemic Sclerosis: The Inside Story' – patients reveal the unseen impact of lung fibrosis

'More than Systemic Sclerosis: The Inside Story' – patients reveal the unseen impact of lung fibrosis.....»»

Category: press-releasesSource: businesswireindiaJul 4th, 2017

IPF patients treated with OFEV® (nintedanib) versus placebo were twice as likely to have improved or stable lung function1

IPF patients treated with OFEV® (nintedanib) versus placebo were twice as likely to have improved or stable lung function1.....»»

Category: press-releasesSource: businesswireindiaMay 25th, 2017

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease.....»»

Category: press-releasesSource: businesswireindiaDec 7th, 2016

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain

Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain.....»»

Category: press-releasesSource: businesswireindiaMay 11th, 2016

Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung

Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung.....»»

Category: press-releasesSource: businesswireindiaApr 7th, 2016

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’.....»»

Category: press-releasesSource: businesswireindiaSep 19th, 2017

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 2017

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 2017.....»»

Category: press-releasesSource: businesswireindiaAug 21st, 2017

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJul 28th, 2017

AstraZeneca shares plunge 16% as lung cancer study fails

AstraZeneca shares plunge 16% as lung cancer study fails.....»»

Category: global-financeSource: business-standardJul 27th, 2017

AstraZeneca shares plunge 15 percent as lung cancer study fails

AstraZeneca shares plunge 15 percent as lung cancer study fails.....»»

Category: topSource: business-standardJul 27th, 2017

AstraZeneca shares plunge 16 percent as lung cancer study fails

AstraZeneca shares plunge 16 percent as lung cancer study fails.....»»

Category: economySource: sifyJul 27th, 2017

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Category: press-releasesSource: businesswireindiaJun 5th, 2017

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients.....»»

Category: press-releasesSource: businesswireindiaDec 5th, 2016

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016